VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) and Biogen Inc. (Nasdaq: BIIB) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience. “ Delivering biologics across the blood brain barrier is one of the most important and long-standing problems in neuroscience,” said Murray McCutcheon, Ph.D., SVP, Partnering at AbCellera. “ We are excited to work with Biogen on thi ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that its scientists will present four posters with data from its T-cell engager programs and platform at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 at the San Diego Convention Center. With its T-cell engager platform, AbCellera is expanding therapeutic opportunities for this modality by generating molecules with the potential for improved efficacy and safety profiles ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company’s Board of Directors for personal reasons, effective March 7, 2024. “ AbCellera continues to expand the frontier of biotech, a nefariously difficult and vital field,” said Peter Thiel. “ I am proud to have helped them with their mission.” Mr. Thiel joined AbCellera’s Board of Directors in November 2020 and served as the Chairman of the ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences: 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024, at 11:50 a.m. Pacific Time (2:50 p.m. Eastern Time) KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Wednesday, March 20, 2024, at 8:15 a.m. Pacific Time (11:15 a.m. Eastern Time) Live audio webcasts of each presentation may be accessed through l ...

AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2023 Results Conference Call February 20, 2024 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & Compliance Officer Carl Hansen - President, CEO Andrew Booth - CFO Conference Call Participants Robyn Karnauskas - Truist Andrea Tan - Goldman Sachs Allison Bratzel - Piper Sandler Stephen Willey - Stifel Steven Mah - Cowen Evan Seigerman - BMO Operator Good afternoon. Thank you for attending AbCellera Biologics Inc. FY 2023 Earnings Results and Business Updat ...

AbCellera Biologics Inc. (ABCL) reported $9.18 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 57.4%. EPS of -$0.17 for the same period compares to -$0.10 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $9.58 million, representing a surprise of -4.19%. The company delivered an EPS surprise of -21.43%, with the consensus EPS estimate being -$0.14.While investors scrutinize revenue and earnings changes year-over-year and how they com ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________ FORM 10-K _____________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39781 _____________________________ AbCellera Biologics Inc. (Exact name ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has AbCellera Biologics Inc. (ABCL) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.AbCellera Biologics Inc. is one of 1077 individual stocks in the Medical sector. Collectively, these companies sit at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individ ...

AbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2023 Results Conference Call November 2, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & Compliance Officer Carl Hansen - President, CEO Andrew Booth - CFO Conference Call Participants Allison Bratzel - Piper Sandler Robyn Karnauskas - Truist Andrea Tan - Goldman Sachs Stephen Willey - Stifel Puneet Souda - Leerink Partners Steven Mah - Cowen Malcolm Hoffman - BMO Operator Good afternoon, and welcome to AbCellera's Third Quarter 2023 Business Updat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _________________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File N ...